<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75737">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02143544</url>
  </required_header>
  <id_info>
    <org_study_id>Heart Institute</org_study_id>
    <nct_id>NCT02143544</nct_id>
  </id_info>
  <brief_title>Intra-aortic Balloon Counterpulsation in Patients Undergoing Cardiac Surgery</brief_title>
  <acronym>IABCS</acronym>
  <official_title>Intra-aortic Balloon Counterpulsation in Patients Undergoing Cardiac Surgery: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <authority>Brazil: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of the study is to evaluate if the preoperative placement of IABP reduces
      clinical complications in high-risk patients undergoing cardiac surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High-risk patients undergoing cardiac surgery are at high risk for myocardial ischemia,
      arrhythmia, cardiogenic shock and other clinical complications. Different therapeutic
      options are available to support these patients in the perioperative period including
      inotropes, vasopressors, and vasodilators, and also assist devices such as intra-aortic
      balloon pump (IABP) and others.

      IABP increases myocardial oxygen supply by increasing diastolic coronary perfusion pressure
      and decreases myocardial oxygen demand by reducing left ventricular afterload. Additionally,
      IABP can also improve cardiac output and systemic perfusion. The hypothesis of this
      randomized and controlled trial is that the placement of IABP immediately before the cardiac
      surgery reduces clinical complications in high-risk patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Composite 30-day mortality or major morbidity (mechanical ventilation &gt; 48 hours, mediastinitis, surgical reexploration, stroke, cardiogenic shock, acute renal failure)</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Composite outcome of 30-day mortality or incidence of patients presenting a major complication according to Society of Thoracic Surgeons (STS): mechanical ventilation &gt; 48 hours, mediastinitis, surgical reexploration, stroke, cardiogenic shock and acute renal failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of days during mechanical ventilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IABP complications</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of patients presenting one of the following: lower limb ischemia, mesenteric ischemia or bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of vasoactive agents</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of days and dose of inotropes and vasopressors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-major complications</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incidence of the following: neurologic, cardiovascular, renal, hematological and infectious complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of hemodynamic data</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison of the following hemodynamic data between groups: heart rate, arterial pressure and cardiac output.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of biomarkers</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison of the following biomarker levels between groups: pro-BNP (Brain natriuretic peptide), troponin I and Neutrophil gelatinase-associated lipocalin  (NGAL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic parameters</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison of the following echocardiographic parameters between groups: left ventricular ejection fraction, cardiac output, left ventricular diastolic diameter, left ventricular systolic diameter and wall motion abnormalities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day mortality</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>60-days mortality</measure>
    <time_frame>60 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year mortality</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison of overall costs between groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Postoperative; Dysfunction Following Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Preoperative intra-aortic balloon pump.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Preoperative placement of the intra-aortic balloon pump.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No preoperative placement of the intra-aortic balloon pump.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intra-aortic balloon pump.</intervention_name>
    <description>Preoperative placement of the intra-aortic balloon pump.</description>
    <arm_group_label>Preoperative intra-aortic balloon pump.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age equal to or higher than 18 years old

          -  EuroSCORE equal to or higher than 6 or ejection fraction equal to or lower than  40%

          -  Written informed consent

        Exclusion Criteria:

          -  Cardiogenic shock

          -  Acute myocardial infarction (AMI) &lt; 48 hours

          -  Mechanical complications of AMI

          -  Peripheral vascular disease (aorta, iliac or femoral)

          -  Severe aortic regurgitation

          -  Neoplasm

          -  Pregnancy

          -  Tachyarrhythmia

          -  Procedures of the aorta

          -  Coagulopathy

          -  Thrombocytopenia

          -  Cardiac transplantation, congenital heart disease or endocarditis

          -  Refusal to consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ludhmila A Hajjar, PhD</last_name>
    <phone>11-26625232</phone>
    <email>ludhmila@usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Graziela Ferreira, Dr</last_name>
    <phone>11-26615367</phone>
    <email>gsrf@uol.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Heart Institute</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludhmila A Hajjar, PhD</last_name>
      <phone>11-26615232</phone>
      <email>ludhmila@usp.br</email>
    </contact>
    <contact_backup>
      <last_name>Graziela Ferreira, Dr</last_name>
      <phone>11-26615367</phone>
      <email>gsrf@uol.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Ludhmila A Hajjar, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 18, 2014</lastchanged_date>
  <firstreceived_date>April 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Ludhmila Abrah√£o Hajjar</investigator_full_name>
    <investigator_title>Professor of Cardiology, University of Sao Paulo</investigator_title>
  </responsible_party>
  <keyword>Intra-aortic balloon counterpulsation</keyword>
  <keyword>Cardiac surgery</keyword>
  <keyword>High-risk patients</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
